PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 3137079-6 1988 Adrenal demedullation partly inhibited but did not completely abolish the effect of TRH on IBAT blood flow and lessened the increase in serum adrenaline caused by TRH. Epinephrine 142-152 thyrotropin releasing hormone Rattus norvegicus 163-166 2512185-2 1989 The intravenous administration of 50 micrograms of TRH produced an increase in plasma epinephrine, cerebral dopamine and a reciprocal decrease in norepinephrine and dopamine in diencephalon and midbrain. Epinephrine 86-97 thyrotropin releasing hormone Rattus norvegicus 51-54 2551657-1 1989 TSH-releasing factor (TRF), administered into the lateral cerebroventricle of adult male rats, elevated plasma concentrations of ACTH, epinephrine, and norepinephrine. Epinephrine 135-146 thyrotropin releasing hormone Rattus norvegicus 0-20 2551657-1 1989 TSH-releasing factor (TRF), administered into the lateral cerebroventricle of adult male rats, elevated plasma concentrations of ACTH, epinephrine, and norepinephrine. Epinephrine 135-146 thyrotropin releasing hormone Rattus norvegicus 22-25 1835988-1 1991 Intrathecal administration of thyrotropin-releasing hormone (TRH) resulted in an increase in plasma epinephrine (E) and glucose levels in conscious rats. Epinephrine 100-111 thyrotropin releasing hormone Rattus norvegicus 30-59 2891452-5 1988 The plasma levels of norepinephrine and epinephrine were increased by TRH, while there was no change in plasma renin activity or vasopressin. Epinephrine 24-35 thyrotropin releasing hormone Rattus norvegicus 70-73 3080257-3 1986 In contrast, following TRH administration (4 mg/kg, iv), an increase in mean arterial pressure was associated with significant increases in plasma epinephrine, norepinephrine, and corticosterone. Epinephrine 147-158 thyrotropin releasing hormone Rattus norvegicus 23-26 6813757-7 1982 It was found that intracerebroventricular pretreatment of animals with TRH, although causing no change in the epinephrine-induced pressor effect, did reduce the epinephrine-induced reflex bradycardia in rats. Epinephrine 161-172 thyrotropin releasing hormone Rattus norvegicus 71-74 9722189-9 1998 The plasma levels of epinephrine, norepinephrine, and glucagon rose significantly after TRH. Epinephrine 21-32 thyrotropin releasing hormone Rattus norvegicus 88-91 8845008-8 1996 administration of thyrotropin releasing hormone (TRH) (10 nmol/animal) also induced increases in plasma levels of adrenaline and noradrenaline, however, these increases were not modified by i.c.v. Epinephrine 114-124 thyrotropin releasing hormone Rattus norvegicus 18-47 7862266-3 1994 All TRH doses studied enhanced blood pressure and noradrenaline and adrenaline secretion. Epinephrine 53-63 thyrotropin releasing hormone Rattus norvegicus 4-7 1835988-1 1991 Intrathecal administration of thyrotropin-releasing hormone (TRH) resulted in an increase in plasma epinephrine (E) and glucose levels in conscious rats. Epinephrine 100-111 thyrotropin releasing hormone Rattus norvegicus 61-64 1681438-6 1991 These observations suggest that TRH-induced hyperglycemia results from at least two effects: a direct neural effect on the liver including a suppressive effect of epinephrine on insulin secretion (contributing about 79% to the total hyperglycemic effect) and a direct effect of epinephrine on the liver (contributing about 21% to the total hyperglycemic effect). Epinephrine 163-174 thyrotropin releasing hormone Rattus norvegicus 32-35 1681438-6 1991 These observations suggest that TRH-induced hyperglycemia results from at least two effects: a direct neural effect on the liver including a suppressive effect of epinephrine on insulin secretion (contributing about 79% to the total hyperglycemic effect) and a direct effect of epinephrine on the liver (contributing about 21% to the total hyperglycemic effect). Epinephrine 278-289 thyrotropin releasing hormone Rattus norvegicus 32-35 2113409-4 1990 administration of TRH (0.6 and 3 nmol) at the T8-10 vertebral level resulted in a dose-related increase in epinephrine (E), norepinephrine (NE), and glucose levels, which was suppressed by prior administration of the ganglionic blocker, hexamethonium (1.5 mg/100 g b. Epinephrine 107-118 thyrotropin releasing hormone Rattus norvegicus 18-21